Navigation Links
Arpida Announces Full Year 2008 Financial Results
Date:2/25/2009

REINACH, Switzerland, February 25 /PRNewswire-FirstCall/ -- Arpida Ltd (SIX: ARPN) announced today its financial results for the year ending 31 December 2008.

    2008 Key Events

      - Setback in regulatory process for intravenous iclaprim in US
      - Restructuring and focus on iclaprim
      - Top-line results of "intravenous-to-oral" Phase II trial with oral
        iclaprim
      - Leadership change
      - Share placing

    Cash and financial investments of CHF 38.7 million at 31 December 2008

    Post-Year-End Event

      - January 2009: FDA issues Complete Response Letter

    2009 Priorities

      - Finalise restructuring
      - Design a roadmap for approval of intravenous iclaprim
      - Consider and develop strategic options

Dr Jurgen Raths, President and CEO, commented: "The negative FDA response of last January was a serious blow to our company and all of its stakeholders. The steps we have announced and executed, though painful, were unavoidable. We are currently pursuing several strategies to maximise shareholder value. This includes partnering, mergers and acquisitions as well as the disposal of certain assets as we do not have the money nor the time required to further develop iclaprim on our own."

CFO Harry Welten, MBA, added: "Our cash balance at year-end 2008 was in line with our earlier guidance. We maintain our forecast that cash and financial investments will amount to approximately CHF 17 million at year-end 2009."

    Financial review for twelve months to 31 December 2008

    Key financial indicators


    CHF million                        2008    2007

    Research and development expenses (43.8)  (45.0)
    Management and general expenses   (13.4)  (15.4)
    Restructuring expenses            (12.6)      -
    Total operating expenses          (69.9)  (60.4)
    Net result                        (66.5)  (59.1)

   
'/>"/>
SOURCE Arpida Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... MN , May 1, 2015 /PRNewswire/ - BioAmber ... producing sustainable chemicals, today announced that it has priced an ... stock at a price of $9.00 per share, and ... to purchase up to an additional 585,000 shares of ... will be $35.1 million.  The offering is expected to close ...
(Date:5/1/2015)... , May 1, 2015 ... Genetic Technologies Ltd (NASDAQ: GENE ), Agilent ... Scientific Inc. (NYSE: TMO ), Sequenom Inc. ... PKI ). Free research report on Genetic ... On Thursday, April 30, 2015, the NASDAQ Composite ...
(Date:4/30/2015)... Blythewood, South Carolina (PRWEB) May 01, 2015 ... steam system services, is extremely proud to announce that ... have been named as a winner of a Queen’s ... business success for the design and manufacture of a ... is the revolutionary alternative to traditional steam flow ...
(Date:4/30/2015)... - BioAmber Inc. (NYSE: BIOA ), an industrial ... commenced an underwritten public offering of its common stock.  ... 30-day option to purchase up to an additional 15 ... the public offering. The offering is subject to market ... whether or when the offering may be completed, or ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 2Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 3Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 4Life Sciences Tools and Services Stocks on our Radar -- Genetic Technologies, Agilent Technologies, Thermo Fisher Scientific, Sequenom, and PerkinElmer 5Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... Multiple Fields, Strengthening the Molecular Bioassays Market , ... Based on its recent analysis of the molecular ... with the 2009 Frost & Sullivan North America ... pioneering Tag-lite(TM) technology for cell surface receptor investigation, ...
... , PHILADELPHIA and LONDON, June 9 /PRNewswire/ -- ... reported today that, despite difficult economic times, renewals of ... many existing customers have even added new content to ... is the world,s largest citation database, providing researchers, administrators, ...
... Executive to Lead Personalized Medicine Company in Next Phase of Growth ... , a personalized medicine company, announced today ... new President and CEO. , , Burns comes to ... strategic management of science and technology for pharmaceutical, diagnostic, and biotech ...
Cached Biology Technology:Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 2Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 3Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 4Frost & Sullivan Recognizes Cisbio Bioassays for Technology Innovation 5Web of Science(R) Renewals Remain Strong Despite Tough Economic Climate 2AssureRx Adds New CEO 2
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... occur in sports and in combat, but health experts ... head movements during these activities pose the greatest risks ... have developed a powerful new computer-based process that helps ... injuries. This approach could lead to new medical treatment ...
... 12, 2013The foodborne bacteria Listeria monocytogenes sickens ... many more worldwide, killing about 25-30% of those infected. ... L. monocytogenes , and current methods for detecting the ... method for developing an inexpensive biosensor to detect the ...
... maxillary sinuses. Those bulbous pouches on either side of the ... sinus infections than anything else. They were thought to be ... present value. Yet researchers led by the University of ... role in the shape and function of the human nose, ...
Cached Biology News:Computer model may help athletes and soldiers avoid brain damage and concussions 2Computer model may help athletes and soldiers avoid brain damage and concussions 3Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis 2Low-cost nano-biosensor to detect foodborne pathogen that causes listeriosis 3The nose's unheralded neighbor 2The nose's unheralded neighbor 3